Clinical Trials

Title   CX-1158-101 Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor CB-1158 as a Single Agent and in Combination with Immune Checkpoint Therapy in Patients with Advanced/Metastatic Solid Tumors
Description   This study is an open-label Phase 1 evaluation of CB-1158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.
IRB Number   17-316
Treatment   Oncology - Lung Cancer
Status   Active
Start Date   08/17/2017
Principal Name   Sachin Pai, MD
Contact Name   Kathleen Ollis

Email Newsletters

Connect With Us